ESMO Media Releases

More than three quarters of oncology specialists in Europe, South America and Asia believe their patients are not always well enough informed about the treatment options available to them

New initiative aims to promote exchange of ideas among female oncologists and support women with cancer in Greece

For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival

Long-term follow-up from CLEOPATRA study presented at ESMO 2014 demonstrates ‘unprecedented’ benefit

Patients whose lung cancer has developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival from continued treatment with the drug in addition to chemotherapy.

Phase III trials presented at the ESMO 2014 Congress report major advances in supportive care for cancer patients.

Study using thymidylate synthase as a predictive and prospective biomarker. Report on a trial with a drug that targets the folate receptor.

The first direct comparison of treating non-squamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free survival, although docetaxel was associated with more frequent adverse events.

One of the most exciting features of immune checkpoint inhibitors (ICIs) is that they provide impressive tumour responses in metastatic cancers of different histologies

Phase III trial indicates the drug is safe and well tolerated in advanced non-small cell lung cancer

Rolapitant reduces nausea and vomiting in patients receiving cisplatin-based chemotherapy

Presentations at ESMO 2014 examine the impact of in-utero exposure to chemotherapy and radiotherapy; the safety of lymph node biopsy in pregnancy; and the outcomes of unplanned pregnancy during cancer treatment